Meningococcemia primary prevention: Difference between revisions
Jump to navigation
Jump to search
Created page with "{{Meningococcemia}} {{CMG}} ==Overview== Before antibiotics the case fatality rate was over 50%, particularly dangerous in infants and elderly (84% and 72% respectively). No..." |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Meningococcemia}} | {{Meningococcemia}} | ||
{{CMG}} | {{CMG}} | ||
Revision as of 15:51, 15 February 2013
|
Meningococcemia Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Meningococcemia primary prevention On the Web |
|
American Roentgen Ray Society Images of Meningococcemia primary prevention |
|
Risk calculators and risk factors for Meningococcemia primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Before antibiotics the case fatality rate was over 50%, particularly dangerous in infants and elderly (84% and 72% respectively). Now it is often as low as 8% in major medical centers.
Primary Prevention
Current vaccines have polysaccharides of groups A, C, Y, and W-135. No vaccine available presently for group B disease since the polysaccharide is not sufficiently immunogenic to produce a reliable antibody response in humans to be effective.